Dr. Lal Path Labs Ltd. has informed the Exchange regarding Outcome of Board Meeting held on July 31, 2025.
LALPATHLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts more than Nifty Smallcap 250 and 1.8 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Dr. Lal PathLabs approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025) along with a clean limited review report from Deloitte Haskins & Sells LLP. The Board also declared an interim dividend of Rs. 6 per equity share (60% on face value of Rs. 10), with a record date of August 6, 2025, and payment to be made within 30 days. Additionally, the Board amended the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information. The results for the corresponding quarter ended June 30, 2024 have been restated to give effect to the distribution of Suburban Diagnostics' business undertaking to the Parent on a going-concern basis, accounted as a common control transaction. A deferred tax credit of Rs. 408 million was recognized in Q4 FY25 relating to the SDIPL transaction.
Shareholders benefit from a Rs. 6 interim dividend signaling consistent cash returns, while the clean limited review report and restatement of prior period numbers (due to the SDIPL consolidation) reflect transparent governance with no auditor qualifications.